Depixus’ CEO to present at the VIB conference: Revolutionizing Next-Generation Sequencing

Read More

Gordon Hamilton, CEO of Depixus will present the latest results from the company at the Revolutionizing Next-Generation Sequencing meeting, which will be held 25-26 March 2019, in Antwerp, Belgium in a talk entitled “Revealing the living genome: direct decoding of DNA, RNA and modified bases using Depixus’ novel technology.”   From the conference website: After two successful editions (Jan…

Depixus awarded a €2.05m grant through the EU’s H2020 SME Instrument Phase 2 programme

Read More

Depixus announced today that it has been awarded a €2.05m grant through the European Union’s prestigious H2020 SME Instrument Phase 2 programme.   The grant will fund an ambitious project to accelerate commercial development of high-throughput version of Depixus’ instrument system known as MAGNA Digital. This instrument system will be used to reveal important new layers of genetic…

PicoSeq announces corporate name change to Depixus

Read More

PicoSeq announced today that it is changing its corporate name to Depixus. “The name change reflects the company’s breadth of interest across both genetic and epigenetic analysis, with our technology being developed for applications far beyond just DNA sequencing” said Gordon Hamilton, Depixus’ Président (CEO). The new name is effective immediately and will be implemented across the company over…

PicoSeq opens new offices and labs in both France and the UK

Read More

PicoSeq have moved their Paris labs and offices to a new location: 3-5 Impasse Reille in the 14th Arrondissement and have also opened a new R&D base near Cambridge, UK. “These new facilities will allow us to significantly expand our team and the scope of our R&D activities” commented CEO Gordon Hamilton. Contact details for our French and UK R&D sites can be found here.  

Chas André joins PicoSeq as Chief Technology Officer

Read More

Effective immediately, Chas André, Ph.D. has joined the PicoSeq leadership team as Chief Technology Officer. Dr. André comes from Thermo Fisher Scientific, where he was R&D Group Manager in Molecular Clinical Diagnostics in Helsinki, Finland. Previously, he has worked for a diverse range of molecular tools companies in Europe and the U.S. He has degrees in Biology and genetics from The…